Form 4: Unity Biotechnology Director Acquires 10,000 Stock Options

Keith R. Leonard, a director at Unity Biotechnology, acquired 10,000 stock options on June 21, 2024, exercisable for common stock.

Summary

• Keith R. Leonard, a director of Unity Biotechnology, Inc. (UBX), filed a Form 4 on June 21, 2024.
• The filing reports a transaction where Leonard acquired 10,000 stock options.
• These options have an exercise price of $1.38.
• The options vest and become exercisable on the earlier of June 21, 2025, or the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.
• The options expire on June 20, 2034.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates